Risk of ischaemic stroke associated with antiepileptic drugs

Cerebrovascular disorders have occurred more frequently in some Central Nervous System (CNS) disorders, such as epilepsy. Some CNS drugs have been associated with increased stroke risk. Our aim was to estimate the risk of ischaemic stroke in patients exposed to antiepileptic drugs (AED). Population-...

Descripción completa

Detalles Bibliográficos
Autores: Giner-Soriano, Maria|||0000-0003-3750-9233, Marsal, Josep Ramon|||0000-0003-0675-6119, Gomez-Lumbreras, Ainhoa|||0000-0002-3916-0402, Morros, Rosa|||0000-0001-6752-8748
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:255596
Acceso en línea:https://ddd.uab.cat/record/255596
https://dx.doi.org/urn:doi:10.1186/s12883-021-02237-1
Access Level:acceso abierto
Palabra clave:Antiepileptic drugs
Stroke
Drug exposure
Electronic health records
Primary healthcare
Descripción
Sumario:Cerebrovascular disorders have occurred more frequently in some Central Nervous System (CNS) disorders, such as epilepsy. Some CNS drugs have been associated with increased stroke risk. Our aim was to estimate the risk of ischaemic stroke in patients exposed to antiepileptic drugs (AED). Population-based matched case-control study using SIDIAP database, based in electronic health records from primary healthcare from Catalonia, Spain. Cases were those patients with a registered diagnosis of first stroke during 2009-2014. Up to 10 controls were selected for each case and matched by sex, age, and geographic area and without a prior diagnosis of stroke. We considered global drug exposure to AED, past and current exposure and exposure in monotherapy to each AED. 2,865 cases and 19,406 controls were exposed to AED during the study period. Global exposure to levetiracetam [(OR3.3, CI95 % 2.8-4.0)], phenytoin [OR1.5, CI95 % 1.2-41.9)], and valproic acid [(OR 1.3, CI95 % 1.1-1.6)], showed significantly association to ischaemic stroke that was also maintained with current exposure of levetiracetam [OR4.1, CI95 % 3.3-5.2)] and valproic acid [OR1.4, CI95 % 1.1-1.9)]. Current levetiracetam monotherapy showed a very high risk of ischaemic stroke [(OR 5.1, CI95 % 3.7-6.9)]. Drugs used for other conditions than epilepsy (pregabalin, gabapentin) were the most used AED and both did not show a risk. Levetiracetam shows a risk for stroke even when assessed in current monotherapy. The lack of data regarding the link with diagnosis and severity in our study makes it necessary to conduct further studies to confirm or dismiss our results, focussing on levetiracetam. The online version contains supplementary material available at 10.1186/s12883-021-02237-1